The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / May / Characterizing Liposomes for Drug Delivery
Manufacture Development & Clinical Drug Delivery Regulation & Standards Sponsored

Characterizing Liposomes for Drug Delivery

05/28/2015 1 min read

Sponsored By

Share

Researchers examine the application and usefulness of nanoparticle tracking analysis and dynamic light scattering techniques in the characterization of liposomes used as drug delivery vehicles.

Liposomes are fast becoming a preferred vehicle for delivering therapeutic drug molecules to target sites – meaning techniques to measure the size, concentration and zeta potential of the preparation are growing in importance For a drug delivery vehicle to be successful, it will ideally localise and target the therapeutic agent to the site of interest and enable a measurable drug interaction with the affected tissue. Used increasingly for this purpose are liposomes, whose applications now include both systemic and topical drug delivery. With the capacity for formulation as liquids, solids or semi-solids, liposomes are being used in treatments ranging from targeting fungal infections to hepatitis A and acute lymphoblastic leukaemia.

The physical characterisation of liposomes plays an important role in supporting the development of appropriate formulations. Here, we examine the contribution made by the complementary techniques of Nanoparticle Tracking Analysis (NTA) for size analysis and light scattering (dynamic and electrophoretic) for size and zeta potential measurement.  ‘Go-To’ Vehicles Liposomes are artificially prepared spherical vesicles that are composed of a lipid bilayer. They were originally used as model systems to study membrane properties such as permeability. Given their ability to incorporate water-soluble materials in their aqueous volume or oil-soluble materials in the lipid bilayer, recent applications for liposomes have focused on their suitability for use as drug delivery vehicles. By controlling the lipid composition and/or through surface modification, liposomes can be designed for specific applications. They may be single-or multi-layered, are biodegradable and essentially non-toxic, and can be produced in different sizes. Their ability to carry both hydrophilic and hydrophobic payloads makes them very versatile. Furthermore, surface modification with the addition of antibodies or peptides, for instance, enables targeting of drugs at specific biological sites or can enhance the longevity of the drug delivery system in vivo. These properties are helping liposomes become the drug delivery system of choice for many developers. Many pharmaceutical uses of liposomes have been described for, among other applications, protecting therapeutic agents against the gastrointestinal environment and facilitating gastrointestinal transport of compounds; targeting and restricting a drug to a particular site; enhancing solubilisation; and improving drug intracellular uptake (1). Topical applications of liposome preparations are also attracting considerable interest both for pharmaceutical and cosmetic use. The mechanisms through which liposomes can deliver drug molecules to target sites include diffusion and, more commonly, direct cell fusion. In the latter process, the lipid bilayer of the liposome will fuse with other bilayers – the cell membrane, for example – thereby transporting the contents of the liposome into the target cell. Click here to see the full article

Malvern Instruments provides the materials and biophysical characterization technology and expertise that enable scientists and engineers to understand and control the properties of dispersed systems. These systems range from proteins and polymers in solution, particle and nanoparticle suspensions and emulsions, through to sprays and aerosols, industrial bulk powders and high concentration slurries. Used at all stages of research, development and manufacturing, Malvern’s materials characterization instruments provide critical information that helps accelerate research and product development, enhance and maintain product quality and optimize process efficiency. Our products reflect Malvern’s drive to exploit the latest technological innovations and our commitment to maximizing the potential of established techniques. They are used by both industry and academia, in sectors ranging from pharmaceuticals and biopharmaceuticals to bulk chemicals, cement, plastics and polymers, energy and the environment. Malvern systems are used to measure particle size, particle shape, zeta potential, protein charge, molecular weight, mass, size and conformation, rheological properties and for chemical identification, advancing the understanding of dispersed systems across many different industries and applications. Headquartered in Malvern, UK, Malvern Instruments has subsidiary organizations in all major European markets, North America, Mexico, China, Japan and Korea, a joint venture in India, a global distributor network and applications laboratories around the world. www.malvern.com severine.michel@malvern.com

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Christine Allen
Development & Clinical Small Molecules Interviews
Musings from The Power List: Christine Allen

August 28, 2026

2 min read

Christine Allen believes AI will connect every stage of drug development, but only if it remains guided by human expertise

Phase III Success Marks Milestone for Personalized Cancer Vaccines
Biopharma Industry News Development & Clinical
Phase III Success Marks Milestone for Personalized Cancer Vaccines

August 26, 2026

7 min read

Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field

The Biggest Bottlenecks Holding Back Cell and Gene Therapy
Cell & Gene Development & Clinical Business & Trends
The Biggest Bottlenecks Holding Back Cell and Gene Therapy

August 24, 2026

9 min read

Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges

Musings from The Power List: Daniel Vitt
Small Molecules Drug Discovery Development & Clinical
Musings from The Power List: Daniel Vitt

August 20, 2026

6 min read

From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: